If you are wondering whether Ionis Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already reflected in the price, you are not alone. That is exactly what we are ...

Fintel reports that on December 9, 2025, B of A Securities maintained coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Buy recommendation. Analyst Price Forecast Suggests 5.02% Upside As of ...

AstraZeneca's fair value estimate has nudged up to about $150.26 from roughly $146.44, even as the long run revenue growth ...

Ionis Pharmaceuticals (IONS) caught investor attention after announcing its investigational drug olezarsen earned Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia. The ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares ...

Metagenomi, Inc. (Nasdaq: MGX) (the 'Company”), an in vivo genome editing company capitalizing on its proprietary ...

Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

Ionis Pharmaceuticals Inc. stock reached a 52-week high, hitting 77.07 USD. This milestone reflects a significant upward trend for the biotech company, known for its focus on RNA-targeted therapies.

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference ("RNAI") ...

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

By Padmanabhan Ananthan and Christy Santhosh (Reuters) -The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' drug for a type of genetic disorder that causes extremely high levels ...